PrecisionLife is extending its relationships with some of the COVID-19 collaborative research projects and is offering free use of its analytics platform and support from its data and biomedical science teams to the on-going collaborative efforts of the medical research community of COVID-19 coronavirus.
The PrecisionLife platform can analyze large scale, complex multi-omic and epidemiological data to generate disease insights that are not possible with current tools. It is routinely used to analyze very large anonymized patient datasets (>100,000 patients) and with detailed insights into complex diseases returned within hours.
The platform can be used to help:
- Identify the complex genetic factors associated with patients’ different disease severity and outcomes
- Understanding risk factors such as smoking, gender, ethnicity, blood group and underlying health conditions
- Developing tests to identify whether people are at high- / low-risk for serious forms of the disease
- Informing the hunt for existing drugs that will be effective for given patient sub-groups, especially those at risk of late-stage disease
- Identification of novel drugs targets especially for more serious late-stage disease
To be effective, the PrecisionLife tools require data from a minimum of several hundred COVID-19 patients, ideally including genotype/whole genome sequence with additional data including disease severity, co-morbidities, and epidemiological/phenotype information such as blood group, smoking, gender, ethnicity etc. The methods work hypothesis-free and do not require training.
The PrecisionLife platform has been validated on over 20 complex disease studies and with disease specialists, development partners and in pre-clinical assays/models. Several of these studies have focused on respiratory and immune response/auto-immune diseases.